C18 dihydro Ceramide (d18:0/18:0) – 5 mg

Brand:
Cayman
CAS:
2304-80-5
Storage:
-20
UN-No:
Non-Hazardous - /

C18 dihydro Ceramide is a bioactive sphingolipid and precursor in the de novo synthesis of C18 ceramide (Item No. 19556) that lacks the 4,5-trans double bond.{40697} Increased C18 dihydroceramide lipid levels lead to increased triacylglycerol storage and autophagosome accumulation as well as upregulation of the fibrosis markers α-SMA and FGF2 in Chang and LX-2 liver cells. C18 dihydro Ceramide is elevated in the plasma of pre-diabetics up to 9 years prior to the onset of type 2 diabetes.{40698} It is also elevated in the skin of patients with lesional atopic dermatitis.{40696}  

 

Available on backorder

SKU: 24379 - 5 mg Category:

Description

A bioactive sphingolipid; precursor in the de novo synthesis of C18 ceramide; leads to increased triacylglycerol storage and autophagosome accumulation as well as upregulation of the fibrosis markers α-SMA and FGF2 in Chang and LX-2 liver cells; elevated in the plasma of pre-diabetics and the skin of patients with lesional atopic dermatitis


Formal name: N-[(1S,2R)-2-hydroxy-1-(hydroxymethyl)heptadecyl]-octadecanamide

Synonyms:  C18 Dihydroceramide|Cer(d18:0/18:0)|Ceramide (d18:0/18:0)|N-octadecanoyl-D-erythro-Dihydrosphingosine|N-Stearoylsphinganine

Molecular weight: 568

CAS: 2304-80-5

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Lipids|Sphingolipids||Research Area|Cell Biology|Endomembrane System & Vesicular Trafficking|Autophagy||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Lipid Biochemistry|Sphingolipids